title: Late clonal complications in severe aplastic anemia.
abstract: One hundred and seventy patients with severe aplastic anemia (SAA) were treated in Basel, from 1976 to 1992. Forty one underwent bone marrow transplantation (BMT) and 129 antilymphocyte globulin (ALG) therapy. As of January 1, 1993, 99 of the 170 patients are alive (58% +/- 7%) and the probability to be alive at 15 years is 54% +/- 4%. Until now, 29 patients have developed a clonal complication. All occurred within the ALG group. Nine patients developed a myelodysplastic syndrome (MDS), 16 patients paroxysmal nocturnal hemoglobinuria (PNH) and 4 patients both, PNH and MDS. The cumulative risk of developing a clonal complication after ALG-therapy is 42% +/- 13% at 15 years; for MDS this risk is 26% +/- 8% and for PNH 25% +/- 5%. The development of a clonal disease directly affects long term prognosis. The survival of the patients with stable disease is 81% +/- 10% and 36% +/- 13% for those with clonal evolution (p = 0.001). The most important risk factor is the type of treatment. In contrast to patients treated with ALG, none of the patients treated with BMT developed MDS or PNH (p < 0.001). No other clinical parameter, such as age, sex, etiology of SAA, severity of the disease and splenectomy correlate with an increased risk of developing this complication. In contrast, morphological parameters at the time of diagnosis, during bone marrow regeneration and at remission are indications in this respect.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Departement fur Innere Medizin, Universitätsspital, Basel, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: C
authors.initials: C
authors.lastname: Nissen
authors.forename: B
authors.initials: B
authors.lastname: Speck
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000150:complications* / Q000401:mortality / Q000628:therapy; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002423:Cause of Death; D005260:Female; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000453:epidemiology; D006457:Hemoglobinuria, Paroxysmal / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000453:epidemiology; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D013156:Splenectomy; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D000961:Antilymphocyte Serum